Digital therapeutics (DTx) are evidence-based therapeutic interventions, driven by the high quality software programs, to prevent, manage, or treat a medical disorder or disease. DTx have potential to reduce disease burdens, deliver better clinical outcomes, and improve patients’ lives by offering better ways to manage chronic health conditions.  

Market Dynamics:

Rise in burden of chronic diseases, outbreak of COVID-19 (pandemic), growing adoption of digital healthcare, rise in adoption of novel technologies, and favorable government initiatives (support) are major factors expected to augment growth of the US digital therapeutics market.

For instance, in September 2022, the U.S. Food & Drug Administration (USFDA) announced the launch of the Digital Health Center of Excellence within the Center for Devices and Radiological Health (CDRH). The launch of the Digital Health Center of Excellence is a vital step in furthering the agency’s overarching dedication to the advancement of digital health technology, including mobile health devices, Software as a Medical Device (SaMD), wearables when used as a medical device, and technologies used to study medical products.

Key features of the study:

• This report provides in-depth analysis of the US digital therapeutics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the US digital therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include 2Morrow Inc., ResMed, Pear Therapeutics, Omada Health Inc., Teladoc Health, Lark Technologies, Kaia Health, Fitbit, Cognoa Inc., and Akili Interactive Labs, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The US digital therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the US digital therapeutics market.

Detailed Segmentation:

• U.S. Digital Therapeutics Market, By Application:
  • Treatment & Disease Management
    • Chronic Care
    • Mental Health & Neurological Disorders
    • Others
  • Preventive Care
    • Pre-diabetes
    • Weight Management
    • Others
• U.S. Digital Therapeutics Market, By End User:
  • Healthcare Providers
  • Patients/Individuals
  • Payers
  • Employers
  • Others
• Company Profiles:
  • 2Morrow Inc.
  • ResMed
  • Pear Therapeutics
  • Omada Health Inc.
  • Teladoc Health
  • Lark Technologies
  • Kaia Health
  • Fitbit
  • Cognoa Inc.
  • Akili Interactive Labs